Safety Study of FP-1039 To Treat Cancer

Five Prime Therapeutics, Inc.39 enrolled

Overview

The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Cancer

Interventions

FP-1039DRUG

Intravenous weekly administration

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with metastatic or locally advanced unresectable solid tumors for which standard curative or supportive measures do not exist or are no longer effective * Male or female 18 years of age or older Exclusion Criteria: * Presence or history of melanoma * Primary brain tumor * Presence or history of glaucoma

Locations (2)

Karmanos Cancer Institute

Detroit, Michigan, United States

START (South Texas Accelerated Research Therapeutics)

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Safety and tolerability

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.